Antibodies to LRP4 and Agrin Are Pathogenic in Myasthenia Gravis
At the Junction Where It Happens
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Autoimmune myasthenia gravis (MG) is a T-cell–dependent, B-cell/antibody–mediated disease. The clinical symptoms and signs, as well as the clinical neurophysiologic and pharmacologic dysfunction, are due to abnormalities at the neuromuscular junction (NMJ). In the large majority of patients with generalized MG and ≈50% of patients with ocular MG, antibodies to the postsynaptic nicotinic acetylcholine receptor (AChR) are present in the serum.1 The presence of these antibodies has proved to be a useful test to aid in the diagnosis of autoimmune MG.2 A large number of in vitro, in vivo, and in situ studies, including immunization of experimental animals with AChR and passive transfer of AChR antibodies to animals to reproduce the disease, have demonstrated that AChR immunoglobulin G (IgG) antibodies are pathogenic. They mediate disease through several mechanisms, including activating the classic complement cascade, increasing the rate of normal endocytosis of AChR (modulating antibodies) at the muscle membrane, and blocking the binding site for acetylcholine on the α peptide of AChR via steric hindrance. All these result in less available AChR to bind acetylcholine released from the presynaptic nerve terminal (reviewed by Ruff and Lisak3). The identity of the other pathogenic antibodies was unknown for almost 3 decades until the demonstration of antibodies to muscle-specific kinase (MuSK) in 50% of patients with AChR-seronegative generalized MG.4 Antibodies to MuSK, a protein at the NMJ critical for the development and maintenance of NMJ and the proper positioning and anchoring of AChR, are pathogenic.3 More recently, antibodies to other important constituents of the NMJ, including low-density lipoprotein receptor–related protein 4 (LRP4) and agrin, have been described. Agrin activates LRP4 to interact with MuSK, which, as noted, is critical for proper expression of AChR, allowing normal neuromuscular transmission. The usefulness of these antibodies in the diagnosis of MG in patients without AChR or MuSK antibodies, so-called double-seronegative (DSN) MG, is still under investigation, but only a small percentage of patients with DSN MG have LRP4 and/or agrin antibodies.5
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the author, if any, are provided at the end of the editorial.
See page 467
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan